6533b7d9fe1ef96bd126cede

RESEARCH PRODUCT

Mean velocity of the pulmonary artery estimated by cardiac magnetic resonance as an early prognostic predictor in heart failure.

subject

description

Background and objective: To identify early, non-invasive prognostic indicators in heart failure (HF), with and without associated pulmonary hypertension, by means of cardiac magnetic resonance, and oxidative stress and anti-inflammatory biomarkers such as Trolox (TM) (antioxidant status) and IL-10 (anti-inflammatory cytokine). Patients and methods: We prospectively included 70 patients admitted for new-onset HF. During index admission, mean velocity of the pulmonary artery (mvPA) was measured, and blood Trolox (TM) and IL-10 determined. The study sample was divided in two groups according to the optimal cut-off value for event prediction calculated by the ROC curve (mvPA = 8 cm/s), considering HF-readmission and all-cause mortality as the primary combined event. Results: During a median follow-up of 290 days, 16 events occurred. In patients with preserved right ventricular (RV) function, mvPA <= 8 cm/s was associated with a higher incidence of events during followup, Kaplan-Meier survival analysis (log rank 6.01, p = .014). MvPA did not add prognostic value when RV dysfunction was already established. Trolox (TM) concentration was lower in patients with mvPA <= 8 cm/s. Higher IL-10 expression was associated with a lower incidence of cardiovascular events during follow-up. Conclusion: In HF patients, mvPA <= 8 cm/s predicts a higher rate of cardiovascular events. Specifically, mvPA identifies a higher risk population among patients with preserved RV function, thus confirming its role as an early prognostic indicator. Lower Trolox (TM) concentration in the worse prognosis group concurs with previous studies on oxidative stress in pulmonary hypertension. Higher IL-10 concentration among patients free of cardiovascular events could be a reflection of its anti-inflammatory and thus protective role in HF. (C) 2019 Elsevier Espana, S.L.U. All rights reserved.